Royal Bank of Canada Cuts Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $136.00
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price lowered by Royal Bank of Canada from $143.00 to $136.00 in a report released on Thursday morning, Benzinga reports. The firm currently has a sector perform rating on the stock. Several other equities analysts also recently issued reports on the company. StockNews.com upgraded Neurocrine Biosciences […]
More Stories
BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund, Inc. Announces Monthly Dividend of $0.04 (NYSE:DCF)
BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund, Inc. (NYSE:DCF – Get Free Report) declared a monthly dividend...
First Trust Alternative Absolute Return Strategy ETF (FAAR) to Issue Quarterly Dividend of $0.20 on September 30th
First Trust Alternative Absolute Return Strategy ETF (NASDAQ:FAAR – Get Free Report) declared a quarterly dividend on Wednesday, September 25th,...
First Trust Capital Strength ETF (FTCS) To Go Ex-Dividend on September 26th
First Trust Capital Strength ETF (NASDAQ:FTCS – Get Free Report) announced a quarterly dividend on Wednesday, September 25th, NASDAQ reports....
AGM Group Holdings Inc. (NASDAQ:AGMH) Short Interest Update
AGM Group Holdings Inc. (NASDAQ:AGMH – Get Free Report) was the recipient of a large growth in short interest in...
Raffles Medical Group Ltd (OTCMKTS:RAFLF) Sees Significant Decrease in Short Interest
Raffles Medical Group Ltd (OTCMKTS:RAFLF – Get Free Report) was the recipient of a significant decrease in short interest in...
Short Interest in Legrand SA (OTCMKTS:LGRDY) Decreases By 90.6%
Legrand SA (OTCMKTS:LGRDY – Get Free Report) was the target of a large decline in short interest in September. As...